Ortho-iodohippurate

Iodohippurate
Clinical data

Routes of administration	intravenous
Pharmacokinetic data
Excretion	renal
Identifiers
IUPAC name 2-[(2-iodobenzoyl)amino]acetic acid
Synonyms	Iodohippuric acid, I Hippuran, I OIH, I-Hippuran, I-OIH, Iodobenzoylglycine, Sodium iodohippurate, Sodium o-iodohippurate, ortho Iodohippurate, ortho-Iodohippurate, Orthoiodohippurate, Radio Hippuran, Radio-Hippuran, RadioHippuran, Sodium Iodohippurate ^[1]
CAS Number	147-58-0
PubChem (CID)	8614
ChemSpider	8295
UNII	3Y68K91A3M
Chemical and physical data
Formula	C₉H₈INO₃
Molar mass	304.95 g/mol
3D model (Jmol)	Interactive image
SMILES C1=CC=C(C(=C1)C(=O)NCC(=O)O)I
InChI InChI=1S/C9H8INO3/c10-7-4-2-1-3-6(7)9(14)11-5-8(12)13/h1-4H,5H2,(H,11,14)(H,12,13) Key:CORFWQGVBFFZHF-UHFFFAOYSA-N

Ortho-iodohippurate is an analogue p-aminohippuric acid for the determination of effective renal plasma flow. Labelled OIH has a significantly higher clearance than other radiopharmaceutical yet developed and is eminently suitable for renography. It is eliminated mainly by tubular secretion. In patients with normally functioning kidneys, 85% of the OIH may be found in the urine 30 minutes after intravenous injection.

OIH was first labelled with ¹³¹I by Tubis and colleagues (Tubis, Posnick and Nordyke in 1960) and for many years this was the only radiopharmaceutical for renography. ¹³¹I has a half-life of 8 days and emits high-energy gamma rays (364 KeV) in addition to beta particles. These physical characteristics were acceptable for probe studies when quantities of the order 1-2 MBq (25-50 μCi) were administered, but they are far from ideal for gamma camera studies which demand a higher activity and a gamma ray emission of lower energy. The introduction of OIH labelled with ¹²³I, with its short physical half-life (13 hours) and its gamma emission of 159 KeV has greatly improved the diagnostic potential of renal studies by combining the production of high-quality functional images with the ability to derive a renogram. The only factor limiting its widespread use is restricted availability and the expense involved in its cyclotron production.^[2]

References

↑ Pubchem. "Compound Summary for CID 8614: 2-Iodohippuric acid". National Center for Biotechnology Information, U.S. National Library of Medicine.
↑ Nuclear Medicine in Urology and Nephrology (2 ed.). p. 239. ISBN 1483162419.

Diagnostic agents (V04)

Digestive system

Diabetes	Glucose Tolbutamide

Fat absorption	Vitamin A concentrates

Bile duct patency	Ceruletide Magnesium sulfate Sincalide Sorbitol

Liver functional capacity	Galactose Sulfobromophthalein

Gastric secretion	Betazole Caffeine and sodium benzoate Cation exchange resins Histamine phosphate Methylthioninium chloride Pentagastrin

Exocrine pancreatic function	Bentiromide Pancreozymin cholecystokinin Secretin

Endocrine system

Pituitary function	cortisol Corticorelin Metyrapone GH Pralmorelin Sermorelin Somatorelin

Thyroid function	Protirelin Thyrotropin

Fertility disturbances	Gonadorelin

Tuberculosis

Tuberculin

Renal function

Physiology of the kidneys and acid-base physiology

Renal function

Secretion	clearance Pharmacokinetics Clearance of medications Urine flow rate

Reabsorption	Solvent drag sodium chloride urea glucose oligopeptides protein

Renal function	Glomerular filtration rate Creatinine clearance Renal clearance ratio Urea reduction ratio Kt/V Standardized Kt/V Measures of dialysis Hemodialysis product PAH clearance (Effective renal plasma flow Extraction ratio)

Filtration	Renal blood flow Ultrafiltration Countercurrent exchange Filtration fraction

Hormones

Acid-base balance

Body water: Intracellular fluid/Cytosol

Buffering

Other

This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.